Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P04637 (
p53
)
77,613
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The protein containing the C2 domain has been well documented for its essential roles in endocytosis, cellular metabolism and cancer.
Tac2-N
(
TC2N
) is a tandem C2 domain-containing protein, but its function, including its role in tumorigenesis, remains unknown. Here, we first identified
TC2N
as a novel oncogene in lung cancer.
TC2N
was preferentially upregulated in lung cancer tissues compared with adjacent normal lung tissues. High
TC2N
expression was significantly associated with poor outcome of lung cancer patients. Knockdown of
TC2N
markedly induces cell apoptosis and cell cycle arrest with repressing proliferation in vitro, and suppresses tumorigenicity in vivo, whereas overexpression of
TC2N
has the opposite effects both in vitro and in vivo. Using a combination of TCGA database and bioinformatics, we demonstrate that
TC2N
is involved in regulation of the
p53
signaling pathway. Mechanistically,
TC2N
attenuates
p53
signaling pathway through inhibiting Cdk5-induced phosphorylation of
p53
via inducing Cdk5 degradation or disrupting the interaction between Cdk5 and
p53
. Moreover, the blockade of
p53
attenuates the function of
TC2N
knockdown in the regulation of cell proliferation and apoptosis. In addition, downregulated
TC2N
is involved in the apoptosis of lung cancer cells induced by doxorubicin, leading to
p53
pathway activation. Overall, these findings uncover a role for the
p53
inactivator
TC2N
in regulating the proliferation and apoptosis of lung cancer cells. Our present study provides novel insights into the mechanism of tumorigenesis in lung cancer.
...
PMID:TC2N, a novel oncogene, accelerates tumor progression by suppressing p53 signaling pathway in lung cancer. 3025 75